Chemomab Therapeutics Ltd. EBITDA for the Trailing 12 Months (TTM) ending December 31, 2024: USD -14.74 M

Chemomab Therapeutics Ltd. EBITDA is USD -14.74 M for the Trailing 12 Months (TTM) ending December 31, 2024, a -42.03% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Chemomab Therapeutics Ltd. EBITDA for the Trailing 12 Months (TTM) ending December 31, 2023 was USD -25.43 M, a -10.70% change year over year.
  • Chemomab Therapeutics Ltd. EBITDA for the Trailing 12 Months (TTM) ending December 31, 2022 was USD -28.48 M, a 130.88% change year over year.
  • Chemomab Therapeutics Ltd. EBITDA for the Trailing 12 Months (TTM) ending December 31, 2021 was USD -12.33 M, a 107.35% change year over year.
  • Chemomab Therapeutics Ltd. EBITDA for the Trailing 12 Months (TTM) ending December 31, 2020 was USD -5.95 M.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)